University of Sheffield: Construction begins on new multi-million gene therapy innovation centre

Building work on the University of Sheffield’s Gene Therapy Innovation and Manufacturing Centre (GTIMC) is now underway by Robertson Construction Group on site at the University’s Innovation District. The new centre will be close to existing translational research facilities and will contribute to an ongoing programme of regional investment and regeneration.

The GTIMC is one of three pioneering hubs in a new £18 million network funded by LifeArc and the Medical Research Council (MRC), with support from the Biotechnology Sciences Research Council (BBSRC).

Sheffield is internationally renowned for its world-class neurodegenerative research. This centre will help to accelerate this revolutionary research into promising and innovative treatment options for many rare diseases which currently have no cure.

Sheffield has emerged as one of the leading players in cell and gene therapy and this national network of partners, facilities and training programmes will allow us to keep pace with translational discoveries for new and potentially life changing treatments.

This is an exciting milestone for revolutionary gene therapeutic advances not only for Sheffield and South Yorkshire, but also for the UK

Professor Mimoun Azzouz

Director of the GTIMC and Chair of Translational Neuroscience at the University of Sheffield

Gene therapy is a promising treatment option for more than 7,000 rare diseases that currently have no cure. It aims to treat these conditions by engineering another gene to replace, silence or manipulate the faulty one.

The state-of-the-art centre will bring together academic institutions, NHS trusts, non-profit and industry partners across the north of England, Midlands and Wales enabling academic-led clinical trials of novel gene therapies. The GTIMC will deliver essential translational and regulatory support alongside extensive training and skills programmes to enable upskilling and address shortage of skills in Good Manufacturing Practice (GMP) manufacturing.

This is outstanding news for South Yorkshire and the North of England. It places our region right at the heart of world-class research and innovation into gene therapy. The vital research carried out here will provide hope for thousands of people with devastating genetic diseases.

The fact that South Yorkshire was chosen is very significant – this will build on our region’s expertise in health and well-being research. The centre will be a beacon of medical innovation, will create valuable highly-skilled jobs and boost economic growth.

Dan Jarvis

Mayor of South Yorkshire

Alongside the national network funding from LifeArc, the MRC and BBSRC, as well as support from the South Yorkshire Mayoral Combined Authority, the GTIMC was made possible thanks to a £3 million donation from The Law Family Charitable Foundation, established by Andrew Law and his wife Zoë. This funding was part of a record £5.85 million donation from the University of Sheffield alumnus, which will also see the launch of a new student support programme.

The University of Sheffield is rapidly developing a global reputation in gene therapy. The new Gene Therapy Innovation and Manufacturing Centre will drive innovation and world-class research, while presenting a real opportunity to catalyse the creation of new start-up companies to facilitate commercialisation in the North.

This investment will enhance vital partnerships with biotechnology and pharmaceutical companies to help accelerate gene therapy programmes and clinical trials, at the same time as supporting regional economic growth and job creation.

Andrew Law

Chairman and CEO of Caxton Associates

Construction on the GTIMC is due to complete in summer 2022.

We are delighted to have been selected as the contractor of choice for this design and build project for University of Sheffield. This is our second project for the University, and we look forward to continuing our positive relationship to see the delivery of GTIMC which will further enhance the University’s reputation in gene therapy and support employment opportunities in this important field.

Paul Turner

Regional Managing Director, Robertson Construction Yorkshire and East Midlands

What are Advanced Therapies?
The new GTIMC hub will expand The University of Sheffield’s facilities and expertise by progressing and generating world-class clinical research into advanced therapies, and discovering novel treatments that will benefit patients with life-limiting neurological diseases.

This video highlights how scientists at the Neuroscience Institute, at The University of Sheffield are already breaking new ground within the field of advanced cell and gene therapies.